{
  "main_header": {
    "sid": 239365,
    "name": "Auro Labs.",
    "stock_name": "Auro Labs.",
    "full_name": "Auro Laboratories Ltd",
    "name_url": "stocks-analysis/auro-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "235.00",
    "chg": -18,
    "chgp": "-7.11%",
    "dir": -1,
    "prev_price": "253.00",
    "mcapval": "158.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530233,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE292C01011",
    "curr_date": "Apr 11, 12:51 PM",
    "curr_time": "00:06 AM",
    "bse_nse_vol": "2.08 k",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/auro-labs-239365-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Auro Laboratories Reports Financial Results Indicating Significant Evaluation Decline in December 2024",
        "link": "https://www.marketsmojo.com/news/result-analysis/auro-laboratories-reports-financial-decline-with-score-dropping-to-21-in-december-2024-1040971",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/AuroLaboratorie_quaterlyResult_451773.png",
        "date": "2025-02-17 13:36:44",
        "description": "Auro Laboratories has announced its financial results for the quarter ending December 2024, revealing a significant shift in its financial standing. The company's evaluation score has declined, indicating that its financial metrics have not met expectations, prompting stakeholders to closely monitor its response to these challenges."
      },
      {
        "title": "Auro Laboratories Faces Significant Sales Decline Amidst Financial Adjustments in Q2 FY24",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/auro-laboratories-reports-62-61-decline-in-net-sales-for-h1-fy24-25-337262",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/1/AuroLaboratorie_mojoScore_253574.png",
        "date": "2025-01-27 18:32:30",
        "description": "Auro Laboratories, a microcap in the Pharmaceuticals & Drugs sector, has recently experienced a change in evaluation due to various financial metrics and market conditions. The company reported a significant decline in net sales and profit after tax for the second quarter of FY24, alongside a low debt-to-equity ratio and strong management efficiency."
      }
    ],
    "total": 50,
    "sid": "239365",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/auro-laboratories-239365"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "27-Mar-2025",
      "details": "Intimation of Closure of Trading Window for the quarter and year ended 31st March 2025.",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "04-Mar-2025",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Saloni Siddhartha Deorah",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "27-Feb-2025",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Saloni Siddhartha Deorah",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Auro Laboratories Reports Financial Results Indicating Significant Evaluation Decline in December 2024

2025-02-17 13:36:44

Auro Laboratories has announced its financial results for the quarter ending December 2024, revealing a significant shift in its financial standing. The company's evaluation score has declined, indicating that its financial metrics have not met expectations, prompting stakeholders to closely monitor its response to these challenges.

Read More

Auro Laboratories Faces Significant Sales Decline Amidst Financial Adjustments in Q2 FY24

2025-01-27 18:32:30

Auro Laboratories, a microcap in the Pharmaceuticals & Drugs sector, has recently experienced a change in evaluation due to various financial metrics and market conditions. The company reported a significant decline in net sales and profit after tax for the second quarter of FY24, alongside a low debt-to-equity ratio and strong management efficiency.

Read More

View All News